Logo image of SNTI

SENTI BIOSCIENCES INC (SNTI) Stock Fundamental Analysis

NASDAQ:SNTI - Nasdaq - US81726A2096 - Common Stock - Currency: USD

3.96  -0.03 (-0.75%)

Fundamental Rating

3

Overall SNTI gets a fundamental rating of 3 out of 10. We evaluated SNTI against 571 industry peers in the Biotechnology industry. SNTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNTI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SNTI had negative earnings in the past year.
SNTI had a negative operating cash flow in the past year.
SNTI had negative earnings in each of the past 5 years.
SNTI had a negative operating cash flow in each of the past 5 years.
SNTI Yearly Net Income VS EBIT VS OCF VS FCFSNTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

SNTI's Return On Assets of -122.83% is on the low side compared to the rest of the industry. SNTI is outperformed by 80.46% of its industry peers.
SNTI's Return On Equity of -443.27% is on the low side compared to the rest of the industry. SNTI is outperformed by 79.04% of its industry peers.
Industry RankSector Rank
ROA -122.83%
ROE -443.27%
ROIC N/A
ROA(3y)-49.62%
ROA(5y)-49.82%
ROE(3y)-81.17%
ROE(5y)-85.07%
ROIC(3y)N/A
ROIC(5y)N/A
SNTI Yearly ROA, ROE, ROICSNTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

SNTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNTI Yearly Profit, Operating, Gross MarginsSNTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

5

2. Health

2.1 Basic Checks

SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNTI has been reduced compared to 1 year ago.
Compared to 1 year ago, SNTI has a worse debt to assets ratio.
SNTI Yearly Shares OutstandingSNTI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
SNTI Yearly Total Debt VS Total AssetsSNTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

SNTI has an Altman-Z score of -10.34. This is a bad value and indicates that SNTI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.34, SNTI is not doing good in the industry: 74.42% of the companies in the same industry are doing better.
There is no outstanding debt for SNTI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.34
ROIC/WACCN/A
WACC9.52%
SNTI Yearly LT Debt VS Equity VS FCFSNTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

SNTI has a Current Ratio of 1.92. This is a normal value and indicates that SNTI is financially healthy and should not expect problems in meeting its short term obligations.
SNTI has a worse Current ratio (1.92) than 77.80% of its industry peers.
SNTI has a Quick Ratio of 1.92. This is a normal value and indicates that SNTI is financially healthy and should not expect problems in meeting its short term obligations.
SNTI has a worse Quick ratio (1.92) than 75.84% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
SNTI Yearly Current Assets VS Current LiabilitesSNTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SNTI have decreased strongly by -893.05% in the last year.
The Revenue for SNTI has decreased by -100.00% in the past year. This is quite bad
SNTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 65.01% yearly.
EPS 1Y (TTM)-893.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1811.08%
Revenue 1Y (TTM)-100%
Revenue growth 3Y65.01%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -10.73% on average over the next years. This is quite bad
SNTI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 67.25% yearly.
EPS Next Y-848.26%
EPS Next 2Y-10.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year21.74%
Revenue Next 2Y47.44%
Revenue Next 3Y18.22%
Revenue Next 5Y67.25%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SNTI Yearly Revenue VS EstimatesSNTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
SNTI Yearly EPS VS EstimatesSNTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNTI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNTI Price Earnings VS Forward Price EarningsSNTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNTI Per share dataSNTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

SNTI's earnings are expected to decrease with -10.73% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.73%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENTI BIOSCIENCES INC

NASDAQ:SNTI (2/21/2025, 8:00:02 PM)

3.96

-0.03 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)N/A N/A
Inst Owners22.64%
Inst Owner Change-14.38%
Ins Owners3.91%
Ins Owner Change-0.08%
Market Cap19.13M
Analysts82.86
Price Target12.24 (209.09%)
Short Float %2.56%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)100%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1825.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-68.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-15.59
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-7.24
FCFYN/A
OCF(TTM)-7.23
OCFYN/A
SpS0
BVpS3.31
TBVpS3.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.83%
ROE -443.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.62%
ROA(5y)-49.82%
ROE(3y)-81.17%
ROE(5y)-85.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -10.34
F-Score2
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)1337.51%
Cap/Depr(5y)936.96%
Cap/Sales(3y)545.04%
Cap/Sales(5y)812.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-893.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1811.08%
EPS Next Y-848.26%
EPS Next 2Y-10.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y65.01%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year21.74%
Revenue Next 2Y47.44%
Revenue Next 3Y18.22%
Revenue Next 5Y67.25%
EBIT growth 1Y18.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.77%
OCF growth 3YN/A
OCF growth 5YN/A